Medical - Healthcare Information Services
Compare Stocks
2 / 10Stock Comparison
ONMD vs HCAT
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Information Services
ONMD vs HCAT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Healthcare Information Services |
| Market Cap | $32M | $111M |
| Revenue (TTM) | $1M | $311M |
| Net Income (TTM) | $-3M | $-178M |
| Gross Margin | -37.0% | 48.7% |
| Operating Margin | -7.1% | -51.7% |
| Forward P/E | — | 14.1x |
| Total Debt | $570K | $20M |
| Cash & Equiv. | $585K | $51M |
ONMD vs HCAT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 21 | May 26 | Return |
|---|---|---|---|
| OneMedNet Corporati… (ONMD) | 100 | 9.9 | -90.1% |
| Health Catalyst, In… (HCAT) | 100 | 2.9 | -97.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ONMD vs HCAT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ONMD carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.37
- Rev growth 111.4%, EPS growth 83.3%, 3Y rev CAGR 5.6%
- -90.3% 10Y total return vs HCAT's -96.0%
HCAT is the clearest fit if your priority is quality and efficiency.
- -57.2% margin vs ONMD's -206.1%
- -27.4% ROA vs ONMD's -145.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 111.4% revenue growth vs HCAT's 1.5% | |
| Quality / Margins | -57.2% margin vs ONMD's -206.1% | |
| Stability / Safety | Beta 0.37 vs HCAT's 2.05 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +134.4% vs HCAT's -61.4% | |
| Efficiency (ROA) | -27.4% ROA vs ONMD's -145.0% |
ONMD vs HCAT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
ONMD vs HCAT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
HCAT leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HCAT is the larger business by revenue, generating $311M annually — 228.9x ONMD's $1M. Profitability is closely matched — net margins range from -57.2% (HCAT) to -2.1% (ONMD). On growth, ONMD holds the edge at +33.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $1M | $311M |
| EBITDAEarnings before interest/tax | -$10M | -$110M |
| Net IncomeAfter-tax profit | -$3M | -$178M |
| Free Cash FlowCash after capex | -$8M | -$5M |
| Gross MarginGross profit ÷ Revenue | -37.0% | +48.7% |
| Operating MarginEBIT ÷ Revenue | -7.1% | -51.7% |
| Net MarginNet income ÷ Revenue | -2.1% | -57.2% |
| FCF MarginFCF ÷ Revenue | -5.5% | -1.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +33.2% | -6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +26.3% | -2.9% |
Valuation Metrics
Evenly matched — ONMD and HCAT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $32M | $111M |
| Enterprise ValueMkt cap + debt − cash | $31M | $80M |
| Trailing P/EPrice ÷ TTM EPS | -16.02x | -0.62x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 14.15x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 23.18x | 0.36x |
| Price / BookPrice ÷ Book value/share | — | 0.45x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
HCAT leads this category, winning 4 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), HCAT scores 6/9 vs ONMD's 5/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | — | -54.7% |
| ROA (TTM)Return on assets | -145.0% | -27.4% |
| ROICReturn on invested capital | — | -32.9% |
| ROCEReturn on capital employed | — | -34.0% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 |
| Debt / EquityFinancial leverage | — | 0.08x |
| Net DebtTotal debt minus cash | -$15,000 | -$31M |
| Cash & Equiv.Liquid assets | $585,000 | $51M |
| Total DebtShort + long-term debt | $570,000 | $20M |
| Interest CoverageEBIT ÷ Interest expense | -40.79x | -4.79x |
Total Returns (Dividends Reinvested)
ONMD leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ONMD five years ago would be worth $971 today (with dividends reinvested), compared to $305 for HCAT. Over the past 12 months, ONMD leads with a +134.4% total return vs HCAT's -61.4%. The 3-year compound annual growth rate (CAGR) favors HCAT at -49.5% vs ONMD's -55.3% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -21.2% | -31.1% |
| 1-Year ReturnPast 12 months | +134.4% | -61.4% |
| 3-Year ReturnCumulative with dividends | -91.1% | -87.1% |
| 5-Year ReturnCumulative with dividends | -90.3% | -96.9% |
| 10-Year ReturnCumulative with dividends | -90.3% | -96.0% |
| CAGR (3Y)Annualised 3-year return | -55.3% | -49.5% |
Risk & Volatility
Evenly matched — ONMD and HCAT each lead in 1 of 2 comparable metrics.
Risk & Volatility
ONMD is the less volatile stock with a 0.37 beta — it tends to amplify market swings less than HCAT's 2.05 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HCAT currently trades 31.0% from its 52-week high vs ONMD's 22.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.37x | 2.05x |
| 52-Week HighHighest price in past year | $4.22 | $5.06 |
| 52-Week LowLowest price in past year | $0.31 | $0.96 |
| % of 52W HighCurrent price vs 52-week peak | +22.8% | +31.0% |
| RSI (14)Momentum oscillator 0–100 | 53.3 | 66.4 |
| Avg Volume (50D)Average daily shares traded | 5.2M | 730K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $2.50 |
| # AnalystsCovering analysts | — | 22 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +4.5% |
HCAT leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ONMD leads in 1 (Total Returns). 2 tied.
ONMD vs HCAT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ONMD or HCAT a better buy right now?
For growth investors, OneMedNet Corporation (ONMD) is the stronger pick with 111.
4% revenue growth year-over-year, versus 1. 5% for Health Catalyst, Inc. (HCAT). Analysts rate Health Catalyst, Inc. (HCAT) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ONMD or HCAT?
Over the past 5 years, OneMedNet Corporation (ONMD) delivered a total return of -90.
3%, compared to -96. 9% for Health Catalyst, Inc. (HCAT). Over 10 years, the gap is even starker: ONMD returned -90. 1% versus HCAT's -95. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ONMD or HCAT?
By beta (market sensitivity over 5 years), OneMedNet Corporation (ONMD) is the lower-risk stock at 0.
37β versus Health Catalyst, Inc. 's 2. 05β — meaning HCAT is approximately 448% more volatile than ONMD relative to the S&P 500.
04Which is growing faster — ONMD or HCAT?
By revenue growth (latest reported year), OneMedNet Corporation (ONMD) is pulling ahead at 111.
4% versus 1. 5% for Health Catalyst, Inc. (HCAT). On earnings-per-share growth, the picture is similar: OneMedNet Corporation grew EPS 83. 3% year-over-year, compared to -121. 7% for Health Catalyst, Inc.. Over a 3-year CAGR, ONMD leads at 5. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ONMD or HCAT?
Health Catalyst, Inc.
(HCAT) is the more profitable company, earning -57. 2% net margin versus -206. 1% for OneMedNet Corporation — meaning it keeps -57. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HCAT leads at -51. 7% versus -711. 3% for ONMD. At the gross margin level — before operating expenses — HCAT leads at 48. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ONMD or HCAT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ONMD or HCAT better for a retirement portfolio?
For long-horizon retirement investors, OneMedNet Corporation (ONMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
37)). Health Catalyst, Inc. (HCAT) carries a higher beta of 2. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ONMD: -90. 1%, HCAT: -95. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ONMD and HCAT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ONMD is a small-cap high-growth stock; HCAT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.